Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

BACKGROUND: In oncology trials, treatment switching from the comparator to the experimental regimen is often allowed but may lead to underestimating overall survival (OS) of an experimental therapy. OBJECTIVE: This study evaluates the impact of treatment switching from control to olaparib on OS usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Rachel, Hawkins, Neil, Dequen-O’Byrne, Pascale, McCrea, Charles, Muston, Dominic, Gresty, Christopher, Ghate, Sameer R., Fan, Lin, Hettle, Robert, Abrams, Keith R., de Bono, Johann, Hussain, Maha, Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484203/
https://www.ncbi.nlm.nih.gov/pubmed/34478046
http://dx.doi.org/10.1007/s11523-021-00837-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484203/
https://www.ncbi.nlm.nih.gov/pubmed/34478046
http://dx.doi.org/10.1007/s11523-021-00837-y

Ejemplares similares